Table 1.
Clinical characteristics of bloodstream infections in patients with solid tumors. Differences between neutropenic patients with hematologic malignancies and solid tumors.
| Marin et al. 2014 [26] | Anatoliotaki et al. 2004 [27] | Marin et al. 2014 [19] |
|||
|---|---|---|---|---|---|
| Population studied | Patients with solid tumors (neutropenic and non-neutropenic) N = 528 (%) | Patients with solid tumors (neutropenic and non-neutropenic) N = 157 (%) | Neutropenic patients with hematological malignancies N = 493 (%) | Neutropenic patients with solid tumors N = 86 (%) | p |
| Age (years, median, range) | — | 64 (18-83) | 57 (19-89) | 61 (14-79) | <0.001 |
| Male sex | 343 (65) | 68 (47) | 306 (62.1) | 51 (59.3) | 0.63 |
| Underlying disease | |||||
| Hepatobiliary tumor | 99 (19) | 9 (6.6) | |||
| Lung tumor | 95 (18) | 25 (18) | |||
| Lower gastrointestinal tumor | 85 (16) | 15 (11) | |||
| Genitourinary tumor | 65 (12) | 11 (8) | |||
| Breast tumor | 39 (7) | 30 (22) | |||
| Gynecologic tumor | 37 (7) | 21 (15) | |||
| Upper gastrointestinal tumor | 36 (7) | 3 (2.2) | |||
| Head and neck tumor | 30 (6) | 2 (1.5) | |||
| Sarcoma | 14 (3) | 5 (3.6) | |||
| Comorbidities | 242 (46) | 132 (26.8) | 32 (37.2) | 0.052 | |
| COPD | 66 (12.5) | 26 (5.3) | 16 (18.8) | <0.001 | |
| Neutropenia (<500 ) | 80 (15) | 29 (18) | 493 (100) | 86 (100) | NS |
| MASCC risc score <21 | 43 (52) | 145 (31.5) | 40 (50.6) | 0.001 | |
| Severe mucositis (grade III.IV) | — | 23 (15) | 61 (12.4) | 10 (11.6) | 1.00 |
| Previous chemotherapy | 335 (63) | 43 (27) | 440 (89.4) | 84 (97.7) | 0.014 |
| Previous radiotherapy | 72 (14) | 22 (14) | |||
| Corticosteroid therapy (1 month) | 213 (41) | 129 (26.2) | 37 (43) | 0.003 | |
| Central venous catheter | 81 (15.3) | 31 (20) | |||
| Intravenous vascular catheter | 213 (40.3) | — | 427 (86.6) | 25 (29.1) | <0.001 |
| Biliary prosthesis | 74 (14) | ||||
| Urinary catheter | 54 (10) | — | 27 (5.5) | 25 (29.1) | <0.001 |
| Previous antibiotic therapy (1 month) | 193 (37) | 22 (14) | 283 (57.4) | 24 (27.9) | <0.001 |
| Previous invasive procedure | — | 93 (59) | |||
| Axillary temperature ≥ 38°C | 406 (77) | 142 (90.5) | |||
| Site of acquisition | |||||
| Heath care | 300 (57) | 80 (51) | 74 (15) | 59 (68.6) | <0.001 |
| Nosocomial | 145 (27.5) | 55 (35) | 408 (82.9) | 14 (16.3) | <0.001 |
| Community acquired | 83 (16) | 22 (14) | 10 (2) | 13 (15.1) | <0.001 |
| Source of BSI | |||||
| Cholangitis | 111 (21) | — | 2 (0.4) | 3 (3.5) | 0.025 |
| Other abdominal sites | 103 (21) | — | 6 (1.2) | 9 (10.5) | <0.001 |
| Urinary tract | 90 (17) | 35 (22.3) | 12 (2.4) | 9 (10.5) | 0.002 |
| Respiratory tract | 57 (11) | 24 (15.2) | 20 (4.1) | 22 (25.6) | <0.001 |
| Catheter related | 53 (10) | 16 (10.1) | 125 (25.4) | 6 (7) | <0.001 |
| Unknown | 44 (8) | 53 (34) | 25 (5.1) | 4 (4.7) | 1.00 |
| Endogenous source | 29 (5.5) | — | 253 (51.3) | 23 (26.7) | <0.001 |
| Skin and soft tissue | 17 (3) | — | 5 (1) | 4 (4.7) | 0.032 |
| Mucositis | 11 (2) | — | 27 (5.5) | 4 (4.7) | 1.00 |
COPD= Chronic obstructive pulmonary disease.